Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-KRd in Newly Diagnosed Multiple Myeloma
NCT03500445Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Feb 2019
- Primary completion
- Jun 2026
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, carfilzomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by University of Chicago. Started Feb 2019; status: active, not recruiting.
02
Drugs
daratumumabcarfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03500445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500445.